Tumour angiogenesis,anti‐angiogenic therapy and chemotherapeutic resistance |
| |
| Authors: | KA Mander JW Finnie |
| |
| Affiliation: | 1. Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia;2. SA Pathology Centre for Neurological Diseases, Adelaide, South Australia, Australia |
| |
| Abstract: | In order for a tumour to continue to grow and disseminate, it must acquire a new blood supply. Neovascularisation can be enacted by a number of different mechanisms. This dependence of tumour progression on an augmented vascular supply has been exploited by the development of anti‐angiogenic drugs, which are designed to inhibit new blood vessel formation or disrupt existing tumour‐associated vasculature, both leading to ischaemic–hypoxic tumour cell death. However, the clinical benefits of these therapeutic approaches are frequently variable and often transient, the neoplasm sometimes being able to use other neovascularisation mechanisms to maintain its blood supply and thus evade the current anti‐angiogenic therapy. Tumours may also develop a more malignant phenotype following this treatment. Clinical outcomes may be improved by simultaneously inhibiting different angiogenic pathways, abetted by more effective drug delivery regimens such as metronomic chemotherapy and the concurrent use of other antitumour modalities. |
| |
| Keywords: | anti‐angiogenic drugs chemotherapeutic resistance tumour neovascularisation |
|
|
